Adri C Voogd

List of Publications by Year
in descending order

140 papers	6,024 citations	101384 36 h-index	76769 74 g-index
144 all docs	144 docs citations	144 times ranked	6161 citing authors

#	Article	IF	Citations
1	Abstract P3-03-21: Contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: Whart do they mean?. Cancer Research, 2022, 82, P3-03-21-P3-03-21.	0.4	0
2	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. Journal of Clinical Oncology, 2022, 40, 2361-2374.	0.8	45
3	Failure of stereotactic core needle biopsy in women recalled for suspicious calcifications at screening mammography: frequency, causes, and final outcome in a multi-institutional, observational follow-up study. European Radiology, 2022, , .	2.3	0
4	Frequency and diagnostic outcome of bilateral recall at screening mammography. International Journal of Cancer, 2021, 148, 48-56.	2.3	1
5	Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017. International Journal of Cancer, 2021, 148, 2289-2303.	2.3	34
6	Trends in delayed breast cancer diagnosis after recall at screening mammography. European Journal of Radiology, 2021, 136, 109517.	1.2	4
7	ASO Author Reflections: Impact of Preoperative MRI on Patients With Screen-Detected Invasive Breast Cancer Undergoing Breast-Conserving Surgery. Annals of Surgical Oncology, 2021, 28, 5939-5940.	0.7	1
8	The Impact of Preoperative Breast MRI on Surgical Margin Status in Breast Cancer Patients Recalled at Biennial Screening Mammography: An Observational Cohort Study. Annals of Surgical Oncology, 2021, 28, 5929-5938.	0.7	5
9	ASO Visual Abstract: The Impact of Preoperative Breast MRI on Surgical Margin Status in Breast Cancer Patients Recalled at Biennial Screening Mammography: An Observational Cohort Study. Annals of Surgical Oncology, 2021, 28, 432.	0.7	0
10	Rate and predictors of nodal pathological complete response following neoadjuvant endocrine treatment in clinically biopsy-proven node-positive breast cancer patients. European Journal of Surgical Oncology, 2021, 47, 1928-1933.	0.5	4
11	Psychosocial factors and cancer incidence (PSYâ€CA): Protocol for individual participant data metaâ€analyses. Brain and Behavior, 2021, 11, e2340.	1.0	8
12	Nationwide registry study on trends in localization techniques and reoperation rates in non-palpable ductal carcinoma in situ and invasive breast cancer. British Journal of Surgery, 2021, 109, 53-60.	0.1	8
13	Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands. Breast Cancer Research and Treatment, 2021, 187, 245-254.	1.1	3
14	Breast magnetic resonance imaging as a problem solving tool in women recalled at biennial screening mammography: A population-based study in the Netherlands. Breast, 2021, 60, 279-286.	0.9	8
15	A patient- and assessor-blinded randomized controlled trial of axillary reverse mapping (ARM) in patients with early breast cancer. European Journal of Surgical Oncology, 2020, 46, 59-64.	0.5	22
16	Additional Breast Cancer Detection at Digital Screening Mammography through Quality Assurance Sessions between Technologists and Radiologists. Radiology, 2020, 294, 509-517.	3.6	6
17	The effect of breast MRI on disease-free and overall survival in breast cancer patients: a retrospective population-based study. Breast Cancer Research and Treatment, 2020, 184, 951-963.	1.1	4
18	Local staging of ipsilateral breast tumor recurrence: mammography, ultrasound, or MRI?. Breast Cancer Research and Treatment, 2020, 184, 385-395.	1.1	5

#	Article	IF	Citations
19	Delayed breast cancer diagnosis after repeated recall at biennial screening mammography: an observational follow-up study from the Netherlands. British Journal of Cancer, 2020, 123, 325-332.	2.9	8
20	Multifocality in ipsilateral breast tumor recurrence - A study in ablative specimens. European Journal of Surgical Oncology, 2020, 46, 1471-1476.	0.5	4
21	Recall and Outcome of Screen-detected Microcalcifications during 2 Decades of Mammography Screening in the Netherlands National Breast Screening Program. Radiology, 2020, 294, 528-537.	3.6	9
22	Characteristics of screen-detected cancers following concordant or discordant recalls at blinded double reading in biennial digital screening mammography. European Radiology, 2019, 29, 337-344.	2.3	3
23	Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. Annals of Surgery, 2019, 270, 364-372.	2.1	41
24	Population-based study of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ. British Journal of Surgery, 2019, 106, 1488-1494.	0.1	15
25	Predicting the extent of nodal involvement for node positive breast cancer patients: Development and validation of a novel tool. Journal of Surgical Oncology, 2019, 120, 578-586.	0.8	11
26	Utility of diagnostic breast excision biopsies during two decades of screening mammography. Breast, 2019, 46, 157-162.	0.9	6
27	Trends in frequency and outcome of highâ€risk breast lesions at core needle biopsy in women recalled at biennial screening mammography, a multiinstitutional study. International Journal of Cancer, 2019, 145, 2720-2727.	2.3	10
28	Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence. British Journal of Surgery, 2019, 106, 574-585.	0.1	9
29	Low Risk of Development of a Regional Recurrence After an Unsuccessful Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence. Annals of Surgical Oncology, 2019, 26, 2417-2427.	0.7	12
30	Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval. Breast Cancer Research and Treatment, 2019, 175, 419-428.	1.1	3
31	Repeat breast-conserving therapy for ipsilateral breast cancer recurrence: A systematic review. European Journal of Surgical Oncology, 2019, 45, 1317-1327.	0.5	40
32	Clinical Epidemiology and theÂImpact of Co-morbidity on Survival. , 2019, , 1-14.		0
33	Risk of Regional Recurrence After Negative Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence. Annals of Surgical Oncology, 2018, 25, 1312-1321.	0.7	14
34	Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography. Breast, 2018, 38, 101-106.	0.9	8
35	Frequency and characteristics of contralateral breast abnormalities following recall at screening mammography. European Radiology, 2018, 28, 4205-4214.	2.3	3
36	Non-visualized sentinel nodes in breast cancer patients; prevalence, risk factors, and prognosis. Breast Cancer Research and Treatment, 2018, 167, 147-156.	1.1	7

#	Article	IF	Citations
37	Tumour characteristics of bilateral screen-detected cancers and bilateral interval cancers in women participating at biennial screening mammography. European Journal of Radiology, 2018, 108, 215-221.	1.2	1
38	Frequency and characteristics of additionally detected ipsilateral breast lesions following recall at screening mammography. Breast, 2018, 42, 94-101.	0.9	0
39	Impact of the second reader on screening outcome at blinded double reading of digital screening mammograms. British Journal of Cancer, 2018, 119, 503-507.	2.9	20
40	Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status. Breast Journal, 2018, 24, 894-901.	0.4	4
41	The COSMAM TRIAL a prospective cohort study of quality of life and cosmetic outcome in patients undergoing breast conserving surgery. BMC Cancer, 2018, 18, 456.	1.1	17
42	Incorporation of the technologistâ€™s opinion for arbitration of discrepant assessments among radiologists at screening mammography. Breast Cancer Research and Treatment, 2018, 171, 143-149.	1.1	2
43	The rationale for and long-term outcome of incomplete axillary staging in elderly women with primary breast cancer. European Journal of Surgical Oncology, 2018, 44, 1714-1719.	0.5	15
44	Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. Breast Cancer Research and Treatment, 2017, 162, 353-364.	1.1	39
45	Screening outcome in women repeatedly recalled for the same mammographic abnormality before, during and after the transition from screen-film to full-field digital screening mammography. European Radiology, 2017, 27, 553-561.	2.3	0
46	What to Do with Non-visualized Sentinel Nodes? A Dutch Nationwide Survey Study. Annals of Surgical Oncology, 2017, 24, 2155-2160.	0.7	4
47	Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. European Journal of Cancer, 2017, 78, 37-44.	1.3	38
48	Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. Breast Cancer Research and Treatment, 2017, 164, 133-138.	1.1	12
49	Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. Journal of the National Cancer Institute, 2017, 109, .	3.0	55
50	Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers. European Journal of Cancer, 2017, 81, 74-80.	1.3	9
51	Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival. Breast Cancer Research and Treatment, 2017, 164, 157-167.	1.1	37
52	Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer. Breast Cancer Research and Treatment, 2017, 166, 307-314.	1.1	17
53	Long-term prognosis of young breast cancer patients (â‰¤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. BMJ Open, 2017, 7, e017842.	0.8	11
54	Interval breast cancer characteristics before, during and after the transition from screen-film to full-field digital screening mammography. BMC Cancer, 2017, 17, 315.	1.1	10

#	Article	IF	Citations
55	Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure. Breast Cancer Research and Treatment, 2017, 165, 555-563.	1.1	13
56	The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients. Oncotarget, 2017, 8, 11372-11379.	0.8	18
57	Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium. Oncotarget, 2017, 8, 79223-79233.	0.8	21
58	Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands. European Journal of Surgical Oncology, 2016, 42, 956-964.	0.5	26
59	Predictors for extensive nodal involvement in breast cancer patients with axillary lymph node metastases. Breast, 2016, 27, 175-181.	0.9	22
60	Reply to the Letter to the Editor by Wade etÂal. â€œThe importance of the Unit of Analysisâ€• Commentary on: Beugels J etÂal. Complications in unilateral versus bilateral deep inferior epigastric artery perforator flap breast reconstructions: A multicentre study. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2016, 69, 1300-1302.	0.5	0
61	Axillary reverse mapping in axillary surgery for breast cancer: an update of the current status. Breast Cancer Research and Treatment, 2016, 158, 421-432.	1.1	32
62	Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients. European Journal of Surgical Oncology, 2016, 42, 1162-1168.	0.5	21
63	Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium. Oncologist, 2016, 21, 555-562.	1.9	35
64	Sentinel Lymph Node Biopsy and Isolated Tumor Cells in Invasive Lobular Versus Ductal Breast Cancer. Clinical Breast Cancer, 2016, 16, e75-e82.	1.1	7
65	Genetic polymorphisms in UDPâ€glucuronosyltransferase 1A6 and 1A7 and the risk for benign Warthin's tumors of the parotid gland. Head and Neck, 2016, 38, E717-23.	0.9	0
66	Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer. Annals of Surgical Oncology, 2016, 23, 51-57.	0.7	63
67	In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Annals of Oncology, 2016, 27, 256-262.	0.6	69
68	A Dutch Prediction Tool to Assess the Risk of Additional Axillary Nonâ€“Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients. Clinical Breast Cancer, 2016, 16, 123-130.	1.1	16
69	Quality of Life in Patients with Breast Cancerâ€“Related Lymphedema and Reconstructive Breast Surgery. Journal of Reconstructive Microsurgery, 2016, 32, 484-490.	1.0	51
70	Clinical impact of breast MRI with regard to axillary reverse mapping in clinically node positive breast cancer patients following neo-adjuvant chemotherapy. European Journal of Surgical Oncology, 2016, 42, 672-678.	0.5	11
71	Treatment of the Primary Tumour in the Presence of Metastases: Lessons from Breast Cancer. European Urology, 2016, 69, 797-799.	0.9	2
72	The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches. Oncotarget, 2016, 7, 29412-29419.	0.8	11

#	Article	IF	Citations
73	Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium. Oncologist, 2015, 20, 856-863.	1.9	31
74	Benefits of preoperative MRI in breast cancer surgery studied in a large population-based cancer registry. British Journal of Surgery, 2015, 102, 1649-1657.	0.1	26
75	Two decades of axillary management in breast cancer. British Journal of Surgery, 2015, 102, 1658-1664.	0.1	37
76	A head to head comparison of nine tools predicting nonâ€sentinel lymph node status in sentinel node positive breast cancer women. Journal of Surgical Oncology, 2015, 112, 133-138.	0.8	17
77	Iodine seed- versus wire-guided localization in breast-conserving surgery for non-palpable ductal carcinoma in situ. British Journal of Surgery, 2015, 102, 1665-1669.	0.1	12
78	The changing role of axillary treatment in breast cancer: Who will remain at risk for developing arm morbidity in the future?. Breast, 2015, 24, 543-547.	0.9	16
79	Reliability of the Inverse Water Volumetry Method to Measure the Volume of the Upper Limb. Lymphatic Research and Biology, 2015, 13, 126-130.	0.5	12
80	Blinded double reading yields a higher programme sensitivity than non-blinded double reading at digital screening mammography: A prospected population based study in the south of The Netherlands. European Journal of Cancer, 2015, 51, 391-399.	1.3	29
81	Overall survival in patients with a re-excision following breast conserving surgery compared to those without in a large population-based cohort. European Journal of Cancer, 2015, 51, 282-291.	1.3	31
82	Axillary reverse mapping (ARM) in clinically node positive breast cancer patients. European Journal of Surgical Oncology, 2015, 41, 59-63.	0.5	33
83	The Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Invasive Breast Cancer in the Post-ACOSOG Z0011 Trial Era. Annals of Surgical Oncology, 2015, 22, 409-415.	0.7	74
84	Patients with Invasive Lobular Breast Cancer Are Less Likely to Undergo Breast-Conserving Surgery: A Population Based Study in The Netherlands. Annals of Surgical Oncology, 2015, 22, 1471-1478.	0.7	17
85	Contralateral lymph node recurrence in breast cancer: Regional event rather than distant metastatic disease. A systematic review of the literature. European Journal of Surgical Oncology, 2015, 41, 1128-1136.	0.5	51
86	Arbitration of discrepant BI-RADS 0 recalls by a third reader at screening mammography lowers recall rate but not the cancer detection rate and sensitivity at blinded and non-blinded double reading. Breast, 2015, 24, 601-607.	0.9	16
87	A Paradigm Shift in Axillary Breast Cancer Treatment; From â€œTreat All-Except,â€•Toward â€œTreat None-Unlessâ€• Clinical Breast Cancer, 2015, 15, 399-402.	1.1	5
88	Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?. British Journal of Cancer, 2015, 112, 1445-1451.	2.9	183
89	The influence of simultaneous integrated boost, hypofractionation and oncoplastic surgery on cosmetic outcome and PROMs after breast conserving therapy. European Journal of Surgical Oncology, 2015, 41, 1411-1416.	0.5	31
90	Improving the Success Rate of Repeat Sentinel Node Biopsy in Recurrent Breast Cancer. Annals of Surgical Oncology, 2015, 22, 529-535.	0.7	18

#	Article	IF	Citations
91	Repeat sentinel node biopsy should be considered in patients with locally recurrent breast cancer. Breast Cancer Research and Treatment, 2015, 153, 549-556.	1.1	38
92	Impact of the transition from screen-film to digital screening mammography on interval cancer characteristics and treatment â€“ A population based study from the Netherlands. European Journal of Cancer, 2014, 50, 31-39.	1.3	37
93	Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. Journal of the National Cancer Institute, 2014, 106, .	3.0	73
94	Prognostic factors for survival in metastatic breast cancer by hormone receptor status. Breast Cancer Research and Treatment, 2014, 145, 503-511.	1.1	26
95	Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands. Breast, 2014, 23, 63-68.	0.9	15
96	Role of compression stockings after endovenous laser therapy for primary varicosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2014, 2, 289-296.	0.9	37
97	Local recurrence following breast-conserving treatment in women aged 40years or younger: Trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. European Journal of Cancer, 2013, 49, 3093-3101.	1.3	92
98	Patterns and determinants of surgical management of screen detected breast cancer in the South-East Netherlands. Breast, 2013, 22, 713-717.	0.9	7
99	Sentinel Node and Recurrent Breast Cancer (SNARB): Results of a Nationwide Registration Study. Annals of Surgical Oncology, 2013, 20, 620-626.	0.7	55
100	Breast cancer survival in the US and Europe: A CONCORD highâ€resolution study. International Journal of Cancer, 2013, 132, 1170-1181.	2.3	100
101	Microsurgical Techniques for the Treatment of Breast Cancerâ€"related Lymphedema: a Systematic Review. Journal of Reconstructive Microsurgery, 2013, 29, 099-106.	1.0	41
102	The impact of mammography screening on breast cancer incidence. Journal of Comparative Effectiveness Research, 2013, 2, 113-116.	0.6	3
103	Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily Dutch practice.. Journal of Clinical Oncology, 2013, 31, e11558-e11558.	0.8	0
104	A real-world study on implementation of new therapeutic options, especially bevacizumab, in a cohort of HER2-negative metastatic breast cancer patients treated with first-line chemotherapy.. Journal of Clinical Oncology, 2013, 31, e17549-e17549.	0.8	0
105	Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Annals of Oncology, 2012, 23, 2859-2865.	0.6	46
106	Small but significant socioeconomic inequalities in axillary staging and treatment of breast cancer in the Netherlands. British Journal of Cancer, 2012, 107, 12-17.	2.9	18
107	Increased risks of third primary cancers of non-breast origin among women with bilateral breast cancer. British Journal of Cancer, 2012, 107, 549-555.	2.9	23
108	Impact of transition from analog screening mammography to digital screening mammography on screening outcome in The Netherlands: a population-based study. Annals of Oncology, 2012, 23, 3098-3103.	0.6	57

#	Article	IF	Citations
109	Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncology, The, 2012, 13, e148-e160.	5.1	505
110	Histological type is not an independent prognostic factor for the risk pattern of breast cancer recurrences. Breast Cancer Research and Treatment, 2012, 135, 271-280.	1.1	26
111	Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer. Indian Journal of Surgical Oncology, 2012, 3, 50-56.	0.3	0
112	Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer. Breast, 2011, 20, 505-509.	0.9	8
113	Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged â‰¤40Âyears. Breast Cancer Research and Treatment, 2011, 127, 207-215.	1.1	72
114	Improved survival of patients with primary distant metastatic breast cancer in the period of 1995â€“2008. A nationwide population-based study in the Netherlands. Breast Cancer Research and Treatment, 2011, 128, 495-503.	1.1	63
115	Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. Breast Cancer Research and Treatment, 2011, 129, 229-233.	1.1	39
116	Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Research and Treatment, 2010, 120, 9-16.	1.1	101
117	Explaining variations in survival in breast cancer in the Eastern Region of England. Annals of Oncology, 2010, 21, 669-670.	0.6	1
118	Performance of Mammography in Women Aged under 40 Years. Women's Health, 2010, 6, 665-667.	0.7	0
119	Variation in â€˜standard careâ€™ for breast cancer across Europe: A EUROCARE-3 high resolution study. European Journal of Cancer, 2010, 46, 1528-1536.	1.3	66
120	Clinical Epidemiology and the Impact of Co-Morbidity on Survival. , 2010, , 37-50.		0
121	Screening caused rising incidence rates of ductal carcinoma inÂsitu of the breast. Breast Cancer Research and Treatment, 2009, 115, 181-183.	1.1	51
122	Stage migration due to introduction of the sentinel node procedure: a population-based study. Breast Cancer Research and Treatment, 2009, 113, 173-179.	1.1	46
123	Additional Tracer Injection to Improve the Technical Success Rate of Lymphoscintigraphy for Sentinel Node Biopsy in Breast Cancer. Annals of Surgical Oncology, 2009, 16, 1156-1163.	0.7	15
124	The impact of postmastectomy radiotherapy on local control in patients with invasive lobular breast cancer. Radiotherapy and Oncology, 2009, 91, 49-53.	0.3	9
125	On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975â€“2004: a long-term population-based study in southeastern Netherlands. Cancer Causes and Control, 2008, 19, 97-106.	0.8	64
126	Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990â€“2006 in the southeastern Netherlands. European Journal of Cancer, 2008, 44, 1846-1854.	1.3	36

#	Article	IF	Citations
127	Clinical epidemiology of breast cancer in the elderly. European Journal of Cancer, 2007, 43, 2242-2252.	1.3	77
128	Explanatory factors for variation in the use of breast conserving surgery and radiotherapy in the Netherlands, 1990â€“2001. Breast, 2007, 16, 606-614.	0.9	23
129	Margin status and the risk of local recurrence after breast-conserving treatment of lobular breast cancer. Breast Cancer Research and Treatment, 2007, 105, 63-68.	1.1	44
130	Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer, 2006, 6, 179.	1.1	114
131	Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: A population-based study. European Journal of Cancer, 2005, 41, 779-785.	1.3	197
132	Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. European Journal of Cancer, 2005, 41, 2637-2644.	1.3	86
133	Long-term prognosis of patients with axillary recurrence after axillary dissection for invasive breast cancer. European Journal of Surgical Oncology, 2005, 31, 485-489.	0.5	17
134	Comparison of morbidity between axillary lymph node dissection and sentinel node biopsy. European Journal of Surgical Oncology, 2003, 29, 341-350.	0.5	251
135	Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials. Journal of Clinical Oncology, 2001, 19, 1688-1697.	0.8	504
136	Long-Term Results of a Randomized Trial Comparing Breast-Conserving Therapy With Mastectomy: European Organization for Research and Treatment of Cancer 10801 Trial. Journal of the National Cancer Institute, 2000, 92, 1143-1150.	3.0	1,104
137	Family history of breast cancer and local recurrence after breast-conserving therapy. European Journal of Cancer, 1999, 35, 620-626.	1.3	32
138	Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. European Journal of Cancer, 1999, 35, 1828-1837.	1.3	64
139	Changing attitudes towards breast-conserving treatment of early breast cancer in the south-eastern Netherlands: results of a survey among surgeons and a registry-based analysis of patterns of care. European Journal of Surgical Oncology, 1997, 23, 134-138.	0.5	15
140	Comparison of breast-conserving therapy with mastectomy for treatment of early breast cancer in community hospitals. European Journal of Surgical Oncology, 1996, 22, 13-16.	0.5	14